Arrogene

Arrogene is a biotechnology company specializing in the development of targeted nanomedicines for the treatment of brain tumors and other cancers. The company's core technology is the Polycefin platform, a biodegradable polymalic acid-based nanobiopolymer designed to deliver therapeutic agents, such as antisense oligonucleotides, across the blood-brain barrier. By conjugating targeting antibodies like anti-transferrin receptor or anti-EGFR, Arrogene aims to provide site-specific delivery while minimizing systemic toxicity. Their lead programs have focused on glioblastoma multiforme and metastatic brain tumors. The company's approach integrates molecular biology and nanotechnology to create multifunctional drugs that can simultaneously target multiple tumor pathways.